Dhanuka AgritechQ1 FY27
Dhanuka Agritech Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹982P/E: 16.3Market Cap: ₹4.4K CrSector: Fertilizers & Agrochemicals
Management growth scorecard
Revenue
Category 4
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4- →The company expects a small single-digit growth in crop protection volumes for FY 2027, indicating a relatively flat to modest increase in sales.
- →Growth projections have been revised downward due to monsoon delays and associated impact on sowing and demand.
- →Despite a weaker 1Q impacted by delayed monsoon and lower sowing, recovery is anticipated in 2Q and 3Q as sowing catches up in some regions.
- →Demand is expected to remain strong in irrigated areas (about 60% of Indian agriculture), with higher crop protection investments there.
- →The bio-stimulant category is being reworked as a fallback and growth area under stress conditions; detailed guidance to be shared later.
- →The company anticipates market share gains as smaller/unorganized players face regulatory challenges, benefiting organized players like Dhanuka.
- →Bayer product revenues and international expansion are expected to contribute gradually, but exact numbers remain unspecified.
Margin guidance
Category 3- →Management projects a small single-digit growth in crop protection volumes for FY 2027 despite challenges like monsoon deficit and delayed sowing.
- →Revenue growth guidance for FY 2027 has been cut steeply due to uncertain monsoon and weak demand in Q1 and early Q2.
- →There is optimism for improved sowing and revenue pickup in Q2 and Q3, but overall FY 2027 top-line growth is expected to be modest.
- →EBITDA breakeven at Dahej plant appears difficult this year, with expected negative EBITDA of around Rs. 4-5 crore.
- →New product launches and biologics (e.g., MYCORe SUPER, Verdor) contribute over 11% of revenue, supporting future growth.
- →Organized players like Dhanuka are expected to capture more market share as smaller/unorganized players reduce under new regulations.
- →Strong balance sheet and cash generation provide flexibility to invest for future growth despite short-term headwinds.
3 more insights locked — sign up free to unlock
Fundraise plans
- →No explicit mention of any current or planned fundraising through debt or equity in the transcript.
- →The company is described as debt-free with a strong balance sheet.
- →They are exploring inorganic growth opportunities but no specific fundraising is noted.
- →CAPEX plans include around Rs. 100 crore for the Nagpur plant over FY 2027-28, but funding details are not provided.
- →No indication of equity issuance or debt raising; emphasis is on leveraging existing strong balance sheet for growth.
Order book
The transcript does not explicitly mention details related to the current or expected order book or pending orders for Dhanuka Agritech Limited. However, relevant points that may indirectly relate to demand and order outlook include:
- Q1 saw weaker sowing due to monsoon deficit impacting herbicide-heavy crops like soybean and cotton.
- Sowing has caught up in some pockets with better July rains, aiding demand recovery.
- Management remains cautiously optimistic on better momentum in coming quarters despite current challenges.
- Expansion plans include a new 23,000-ton formulation plant at Nagpur expected operational by April 2028, indicating confidence in future demand growth.
- The company expects to launch five new products soon, signaling an active product pipeline to capture market opportunities.
- Discussions indicate ongoing efforts to scale Bayer product distribution internationally, which could contribute to order book growth.
- No specific quantitative order book or pending order data was disclosed during the call.
Capex plans
Yes- →The company has acquired land at Butibori industrial zone, Nagpur, Maharashtra for a new manufacturing plant.
- →The Nagpur plant will be a formulation facility with an estimated CAPEX of around Rs. 200 crore.
- →Proposed capacity of the Nagpur plant is 23,000 metric tons per annum.
- →Expected commissioning timeline for the Nagpur plant is Q4 FY 2028 (around April 2028).
- →The Nagpur facility will feature significant automation to enhance safety and efficiency.
- →The plant has potential for future expansion beyond the initial 23,000 tons capacity.
- →CAPEX of around Rs. 100 crore related to Nagpur is planned across FY 2027 and FY 2028.
- →No overlapping formulation facility is planned at the Dahej chemical synthesis site due to technology and operational differences.
- →Additional CAPEX for Dahej will be communicated later.
How does Dhanuka Agritech rank vs peers in Fertilizers & Agrochemicals?
Pro feature1Dhanuka Agritech
Rev 4Mar 3
See full Fertilizers & Agrochemicals sector rankings
How does Dhanuka Agritech rank in Fertilizers & Agrochemicals?
Compare Dhanuka Agritech against every Fertilizers & Agrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.